a North American health care & life science venture capital firm
The team at Lumira Capital was more than one of Pharmasset's lead investors. Their partners worked tirelessly to ensure our success, helping us diversify our pipeline, establish a partnership with a major pharmaceutical company, attract outstanding board members, and execute a successful IPO in 2007 which let us successfully develop our breakthrough therapy for treating chronic hepatitis C infection.
Schaefer Price - CEO Pharmasset (Acquired by Gilead Sciences)
partnering to transform entrepreneurial vision into economic reality